(Q36887547)

16 August 2017

1 reference

title

Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface (English)

1 reference

16 August 2017

Timothy A McKinsey

1

1 reference

16 August 2017

David A Kass

series ordinal

2

1 reference

16 August 2017

publication date

1 August 2007

1 reference

Nature Reviews Drug Discovery

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

617-635

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2193

16 August 2017

exact match

0 references

cites work

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

1 reference

Na-H exchange acts downstream of RhoA to regulate integrin-induced cell adhesion and spreading

21 January 2018

1 reference

Development of specific Rho-kinase inhibitors and their clinical application

21 January 2018

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA

21 January 2018

1 reference

Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats

21 January 2018

1 reference

Cardiotrophic Effects of Protein Kinase C : Analysis by In Vivo Modulation of PKC Translocation

21 January 2018

1 reference

Hypertrophy of the heart: a new therapeutic target?

21 January 2018

1 reference

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

31 March 2020

1 reference

Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure

31 March 2020

1 reference

Prognostic significance of left ventricular mass change during treatment of hypertension

31 March 2020

1 reference

Left ventricular hypertrophy: the next treatable, silent killer?

31 March 2020

1 reference

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

31 March 2020

1 reference

The Rac and Rho hall of fame: a decade of hypertrophic signaling hits

31 March 2020

1 reference

ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice

31 March 2020

1 reference

Rocks: multifunctional kinases in cell behaviour

31 March 2020

1 reference

Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells

31 March 2020

1 reference

Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death

31 March 2020

1 reference

Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice

31 March 2020

1 reference

ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles

31 March 2020

1 reference

Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)

31 March 2020

1 reference

Signal transduction and regulation in smooth muscle

31 March 2020

1 reference

Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

31 March 2020

1 reference

Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin

31 March 2020

1 reference

Regulation of PTEN by Rho small GTPases

31 March 2020

1 reference

The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease

31 March 2020

1 reference

Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.

31 March 2020

1 reference

Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition

31 March 2020

1 reference

Effect of Rho GTPases on Na-H exchanger in mammalian cells.

31 March 2020

1 reference

Rho-kinase inhibition in the therapy of cardiovascular disease

31 March 2020

1 reference

Rho-kinase is an important therapeutic target in cardiovascular medicine

31 March 2020

1 reference

Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system

31 March 2020

1 reference

Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.

31 March 2020

1 reference

Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice

31 March 2020

1 reference

Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure.

31 March 2020

1 reference

Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts

31 March 2020

1 reference

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

31 March 2020

1 reference

Pleiotropic effects of statins

31 March 2020

1 reference

Statins and myocardial hypertrophy

31 March 2020

1 reference

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

31 March 2020

1 reference

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

31 March 2020

1 reference

Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

31 March 2020

1 reference

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats

31 March 2020

1 reference

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

31 March 2020

1 reference

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

31 March 2020

1 reference

Tor signalling in bugs, brain and brawn

31 March 2020

1 reference

Dysregulation of the TSC-mTOR pathway in human disease

31 March 2020

1 reference

Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy

31 March 2020

1 reference

Rheb fills a GAP between TSC and TOR.

31 March 2020

1 reference

Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy

31 March 2020

1 reference

Adiponectin-mediated modulation of hypertrophic signals in the heart

31 March 2020

1 reference

Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte

31 March 2020

1 reference

Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy

31 March 2020

1 reference

Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase

31 March 2020

1 reference

Rapamycin attenuates load-induced cardiac hypertrophy in mice

31 March 2020

1 reference

The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo

31 March 2020

1 reference

Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload

31 March 2020

1 reference

Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways

31 March 2020

1 reference

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

31 March 2020

1 reference

Glycogen synthase kinase 3beta inhibits myocardin-dependent transcription and hypertrophy induction through site-specific phosphorylation

31 March 2020

1 reference

Protein kinase cascades in the regulation of cardiac hypertrophy

31 March 2020

1 reference

Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure

31 March 2020

1 reference

Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart

31 March 2020

1 reference

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

31 March 2020

1 reference

Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.

31 March 2020

1 reference

Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy

31 March 2020

1 reference

Nuclear targeting of Akt enhances ventricular function and myocyte contractility

31 March 2020

1 reference

Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems

31 March 2020

1 reference

Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels

31 March 2020

1 reference

Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes

31 March 2020

1 reference

Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II

31 March 2020

1 reference

Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes

31 March 2020

1 reference

The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model

31 March 2020

1 reference

Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro

31 March 2020

1 reference

Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium

31 March 2020

1 reference

Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress

31 March 2020

1 reference

Redox-dependent transcriptional regulation

31 March 2020

1 reference

Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation

31 March 2020

1 reference

Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy

31 March 2020

1 reference

Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice

31 March 2020

1 reference

Cardiac-specific overexpression of catalase rescues ventricular myocytes from ethanol-induced cardiac contractile defect.

31 March 2020

1 reference

Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

31 March 2020

1 reference

Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy

31 March 2020

1 reference

Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?

31 March 2020

1 reference

Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart

31 March 2020

1 reference

Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy

31 March 2020

1 reference

Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure

31 March 2020

1 reference

Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy

31 March 2020

1 reference

Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?

31 March 2020

1 reference

Activation of NADPH oxidase during progression of cardiac hypertrophy to failure

31 March 2020

1 reference

NADPH oxidase and heart failure

31 March 2020

1 reference

NOX enzymes and the biology of reactive oxygen

31 March 2020

1 reference

NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy

31 March 2020

1 reference

Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy

31 March 2020

1 reference

Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox

31 March 2020

1 reference

Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice.

31 March 2020

1 reference

Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer

31 March 2020

1 reference

31 March 2020

No .NO from NO synthase

1 reference

Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase

31 March 2020

1 reference

Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load

31 March 2020

1 reference

Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression

31 March 2020

1 reference

Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension

31 March 2020

1 reference

Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure.

31 March 2020

1 reference

Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease

31 March 2020

1 reference

Correction of endothelial dysfunction by tetrahydrobiopterin: new hope for the treatment of arterial hypertension?

31 March 2020

1 reference

Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress

31 March 2020

1 reference

Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats

31 March 2020

1 reference

Cardiac oxidative stress in acute and chronic isoproterenol-infused rats

31 March 2020

1 reference

Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways

31 March 2020

1 reference

Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials

31 March 2020

1 reference

Function of cGMP-dependent protein kinases as revealed by gene deletion.

31 March 2020

1 reference

Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts

31 March 2020

1 reference

Regulation of gene expression by cyclic GMP.

31 March 2020

1 reference

Regulation of cardiac beta-adrenergic response by nitric oxide

31 March 2020

1 reference

Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system

31 March 2020

1 reference

Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway

31 March 2020

1 reference

Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes

31 March 2020

1 reference

Natriuretic peptide signalling: molecular and cellular pathways to growth regulation

31 March 2020

1 reference

Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)

31 March 2020

1 reference

Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes

31 March 2020

1 reference

Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I.

31 March 2020

1 reference

Phospholamban: a crucial regulator of cardiac contractility

31 March 2020

1 reference

Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle

31 March 2020

1 reference

Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure

31 March 2020

1 reference

RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes

31 March 2020

1 reference

Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy

31 March 2020

1 reference

Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria

31 March 2020

1 reference

Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

31 March 2020

1 reference

Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

31 March 2020

1 reference

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.

31 March 2020

1 reference

Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart.

31 March 2020

1 reference

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

31 March 2020

1 reference

Natriuretic peptides: novel therapeutic targets in heart failure

31 March 2020

1 reference

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

31 March 2020

1 reference

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

31 March 2020

1 reference

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

31 March 2020

1 reference

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

31 March 2020

1 reference

Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes

31 March 2020

1 reference

Sildenafil citrate therapy for pulmonary arterial hypertension

31 March 2020

1 reference

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

31 March 2020

1 reference

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

31 March 2020

1 reference

cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism

31 March 2020

1 reference

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

31 March 2020

1 reference

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

31 March 2020

1 reference

Calcineurin: From structure to function

31 March 2020

1 reference

NFAT signaling: choreographing the social lives of cells

31 March 2020

1 reference

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

31 March 2020

1 reference

Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice

31 March 2020

1 reference

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

31 March 2020

1 reference

Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo

31 March 2020

1 reference

MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction

31 March 2020

1 reference

Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth

31 March 2020

1 reference

Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy

31 March 2020

1 reference

Cardiac hypertrophy: the good, the bad, and the ugly

31 March 2020

1 reference

Calcium-calcineurin signaling in the regulation of cardiac hypertrophy

31 March 2020

1 reference

Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo

31 March 2020

1 reference

A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway

31 March 2020

1 reference

GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs

31 March 2020

1 reference

Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo

31 March 2020

1 reference

Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1.

31 March 2020

1 reference

Calsarcins, a novel family of sarcomeric calcineurin-binding proteins

31 March 2020

1 reference

Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins

31 March 2020

1 reference

Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress

31 March 2020

1 reference

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

31 March 2020

1 reference

Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

31 March 2020

1 reference

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

31 March 2020

1 reference

Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling

31 March 2020

1 reference

The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling

31 March 2020

1 reference

A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells

31 March 2020

1 reference

A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy.

31 March 2020

1 reference

Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules

31 March 2020

1 reference

Inhibition of the calcineurin-NFAT interaction by small organic molecules reflects binding at an allosteric site

31 March 2020

1 reference

An introduction to TRP channels

31 March 2020

1 reference

The mammalian TRPC cation channels

31 March 2020

1 reference

Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling

31 March 2020

1 reference

Sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) gene silencing and remodeling of the Ca2+ signaling mechanism in cardiac myocytes

31 March 2020

1 reference

TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy

31 March 2020

1 reference

Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart

31 March 2020

1 reference

TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling

31 March 2020

1 reference

TRPC1 forms the stretch-activated cation channel in vertebrate cells.

31 March 2020

1 reference

TRPC3 channels confer cellular memory of recent neuromuscular activity.

31 March 2020

1 reference

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator

31 March 2020

1 reference

Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds

31 March 2020

1 reference

A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2.

31 March 2020

1 reference

Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2.

31 March 2020

1 reference

Chemical genetics to identify NFAT inhibitors: potential of targeting calcium mobilization in immunosuppression

31 March 2020

1 reference

The multifunctional Ca2+/calmodulin-dependent protein kinases

31 March 2020

1 reference

CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo

31 March 2020

1 reference

The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes

31 March 2020

1 reference

Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes?

31 March 2020

1 reference

Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy

31 March 2020

1 reference

Enhanced protein phosphorylation in hypertensive hypertrophy

31 March 2020

1 reference

Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo

31 March 2020

1 reference

Calcium/calmodulin-dependent protein kinase II activity is increased in sarcoplasmic reticulum from coronary artery ligated rabbit hearts

31 March 2020

1 reference

Expression of Ca2+/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy

31 March 2020

1 reference

The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure

31 March 2020

1 reference

Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts

31 March 2020

1 reference

The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity

31 March 2020

1 reference

Calmodulin kinase II inhibition protects against structural heart disease

31 March 2020

1 reference

Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo

31 March 2020

1 reference

Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II.

31 March 2020

1 reference

Calcium signaling in cardiac ventricular myocytes.

31 March 2020

1 reference

Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels

31 March 2020

1 reference

Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes

31 March 2020

1 reference

Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release

31 March 2020

1 reference

Modulation of cardiac Na(+) and Ca(2+) currents by CaM and CaMKII.

31 March 2020

1 reference

Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure

31 March 2020

1 reference

The fire from within: the biggest Ca2+ channel erupts and dribbles

31 March 2020

1 reference

Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy

31 March 2020

1 reference

Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling

31 March 2020

1 reference

CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy

31 March 2020

1 reference

Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease

31 March 2020

1 reference

Potent and preferential inhibition of Ca2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926

31 March 2020

1 reference

Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme

31 March 2020

1 reference

Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain

31 March 2020

1 reference

PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility

31 March 2020

1 reference

Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC.

31 March 2020

1 reference

Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq

31 March 2020

1 reference

Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition

31 March 2020

1 reference

Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon

31 March 2020

1 reference

The effect of ruboxistaurin on nephropathy in type 2 diabetes

31 March 2020

1 reference

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized cl

31 March 2020

1 reference

Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction

31 March 2020

1 reference

PKC-beta is not necessary for cardiac hypertrophy

31 March 2020

1 reference

Protein Kinase Cα Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy

31 March 2020

1 reference

PKC-alpha regulates cardiac contractility and propensity toward heart failure

31 March 2020

1 reference

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart

31 March 2020

1 reference

Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure

31 March 2020

1 reference

Toward transcriptional therapies for the failing heart: chemical screens to modulate genes

31 March 2020

1 reference

Class II histone deacetylases: versatile regulators

31 March 2020

1 reference

Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development

31 March 2020

1 reference

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

31 March 2020

1 reference

Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2

31 March 2020

1 reference

31 March 2020

1 reference

Myocardin induces cardiomyocyte hypertrophy.

31 March 2020

1 reference

Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A.

31 March 2020

1 reference

The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases

31 March 2020

1 reference

Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization

31 March 2020

1 reference

Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5

31 March 2020

1 reference

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

31 March 2020

1 reference

Identification of a signal-responsive nuclear export sequence in class II histone deacetylases

31 March 2020

1 reference

Regulation of histone deacetylase 4 by binding of 14-3-3 proteins

31 March 2020

1 reference

The CRM1 nuclear export receptor controls pathological cardiac gene expression

31 March 2020

1 reference

Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5

31 March 2020

1 reference

Regulation of cardiac stress signaling by protein kinase d1.

31 March 2020

1 reference

Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes

31 March 2020

1 reference

Protein kinases--the major drug targets of the twenty-first century?

31 March 2020

1 reference

Protein kinase D signaling

31 March 2020

1 reference

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

31 March 2020

1 reference

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding

31 March 2020

1 reference

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy

31 March 2020

1 reference

Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop

31 March 2020

1 reference

Effect of serum triiodothyronine on regulation of cardiac gene expression: role of histone acetylation

31 March 2020

1 reference

Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility

31 March 2020

1 reference

Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population

31 March 2020

1 reference

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

31 March 2020

1 reference

Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor

31 March 2020

1 reference

Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation

31 March 2020

1 reference

Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2

31 March 2020

1 reference

Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4

31 March 2020

1 reference

Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes

31 March 2020

1 reference

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity

31 March 2020

1 reference

Identification and characterization of a sac domain-containing phosphoinositide 5-phosphatase

31 March 2020

1 reference

Acetylation and deacetylation of non-histone proteins

31 March 2020

1 reference

Regulation of cardiac hypertrophy by intracellular signalling pathways

31 March 2020

1 reference

Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction

31 March 2020

1 reference

Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster

31 March 2020

1 reference

Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction

31 March 2020

1 reference

Role of 14-3-3-mediated p38 mitogen-activated protein kinase inhibition in cardiac myocyte survival

31 March 2020

1 reference

Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy

31 March 2020

1 reference

PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

31 March 2020

1 reference

Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy.

31 March 2020

1 reference

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies

31 March 2020

1 reference

Telomere attrition and Chk2 activation in human heart failure

31 March 2020

1 reference

Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles

31 March 2020

1 reference

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload

31 March 2020

1 reference

Raf kinases: oncogenesis and drug discovery

31 March 2020

1 reference

The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin

31 March 2020

1 reference

HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.

31 March 2020

1 reference

Trends in prevalence and outcome of heart failure with preserved ejection fraction

31 March 2020

1 reference

Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry

31 March 2020

1 reference

An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy

31 March 2020

1 reference

Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2193

1 reference

release_ao2wizemkzfozmno4ayeoecm4u

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ao2wizemkzfozmno4ayeoecm4u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference